- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Coadministration of boceprevir with ritonavir-boosted HIV protease inhibitors could reduce drugs' effectiveness
FDA has notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these drugs when they are used together.
FDA has notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these drugs when they are used together.
FDA will be updating the boceprevir drug label to include information about these drug interactions.
In a company press release, Merck said that it has informed US physicians of the results of a recent pharmacokinetic study evaluating drug interactions between boceprevir, the company's oral HCV NS3/4A protease inhibitor, and ritonavir-boosted HIV protease inhibitors in 39 healthy volunteers.
COINFECTED PATIENTS
The safety and efficacy of boceprevir has not been established in patients coinfected with HIV and HCV. Merck does not recommend the coadministration of boceprevir and ritonavir-boosted HIV protease inhibitors.
"Though Victrelis is not indicated for the treatment of chronic HCV in those who are also infected with HIV, we recognize that some physicians have prescribed or may be considering prescribing Victrelis for patients taking ritonavir-boosted HIV protease inhibitors," Robin Isaacs, vice president, clinical research, infectious diseases, Merck Research Laboratories, said in the company press release.
"We felt it was important to share these data as part of our commitment to patient safety and transparency. What is most critical to remember is that all patients taking medicines for chronic HCV or HIV, or both, should not discontinue their medication regimens without first consulting with their physicians," Isaacs said.
In addition to notifying regulatory agencies of these results, Merck has informed the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and the AIDS Clinical Trials Group (ACTG), 2 organizations with whom Merck is collaborating on HCV/HIV coinfection clinical trials. Investigational studies evaluating the effectiveness and safety of boceprevir in patients coinfected with chronic HCV genotype 1 and HIV-1 are ongoing.
CLOSE MONITORING NEEDED
Healthcare professionals who have started patients infected with both chronic HCV and HIV on boceprevir and antiretroviral therapy containing a ritonavir-boosted protease inhibitor should closely monitor patients for HCV treatment response and for potential HCV and HIV virologic rebound.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
